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New formulation of ibuprofen on absorption-rate: A 
comparative bioavailability study in healthy 
volunteers 
 
Abstract 
Background: Enteric-coated capsules are solid dosage forms which are designed to bypass 
the stomach and release the drug in the small intestine. This study was done to compare 
pharmacokinetics of ibuprofen tablet and ibuprofen as enteric-coated capsule using sodium 
alginate beads. 
Methods: A crossover randomized study was performed on 12 healthy volunteers 
receiving a single dose of regular ibuprofen tablet (200 mg) and enteric-coated capsule 
(200 mg). The washout time between the periods was one month. Pharmacokinetic and 
pharmacodynamic blood samples were collected for 16 hours following treatment. High-
performance liquid chromatography (HPLC) method used the following specifications: 
C18 column with 4.6 mm diameter & 25 mm length, the fluorescent detector of excitation 
and emission wavelengths were 224 and 290 nm, respectively. 
Results: After a single oral dose of ibuprofen formulations, the median times to maximum 
concentration were 60 and 240 minutes in ibuprofen tablet (200 mg) and enteric-coated 
capsule, respectively. The maximum levels for the participants receiving ibuprofen tablet 
and enteric-coated capsule were 11.71±1.3 and 10.32±4.19 µg/mL, respectively. The 
pharmacokinetic (PK) modeling data showed the area under curve (AUC) to be 61.51 
hours & 86.62 hours for the group receiving the tablet and the capsule, respectively. 
Conclusion: According to the results, in is concluded that enteric coating may delay the 
onset of ibuprofen effect and increases the duration of action. This formulation has 
advantages over the conventional drug delivery systems as it lengthens the dosing intervals 
and also increases patient compliance for chronic pain. 
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Ibuprofen is a widely known member of non-steroidal anti-inflammatory drugs 
(NSAIDs). It is mostly used as a relieving agent in acute and chronic pains and 
inflammation. Common adverse effects of the NSAIDs e.g. ibuprofen may include 
gastrointestinal (GI) symptoms, such as stomachache, heartburn, gastric ulcers and bleeding (1-
3). These effects mostly occur because ibuprofen is a none-specific COX inhibitor (4-6). 
Following oral administration, ibuprofen tablet is disintegrated and dissolved in the gastric 
fluids, which may lead to such painful side effects (7, 8). Most analgesics are formulated 
to reach higher blood concentration in a lower duration, to relieve the acute or sub-acute 
pain more rapidly (9, 10). However, in the case of patients with chronic inflammatory 
conditions that experience mild to moderate pain, achieving a formulation that can 
maintain steady- state concentrations in blood, is more effective in treatment (11, 12). 
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To overcome the above mentioned problems, it is 
suggested to encapsulate ibuprofen in sodium alginate beads, 
coated with calcium chloride (13, 14). Such a formulation 
will help to bypass disintegration in gastric fluids, directly 
reaching to the alkaline medium of duodenum. In addition to 
avoiding the gastrointestinal pains caused by the 
conventional formulation, this method will also help 
maintain a reasonable blood concentration and therefore 
have more long-term effects. However, due to the 
formulation of ibuprofen and the pharmacokinetics of 
different formulations, the effective treatment with COX2 
inhibition has been established previously (15). This clinical 
study was done firstly to investigate a special formulation for 
designing sodium alginate that can thoroughly encapsulate 
ibuprofen formulations evaluated at a dose of 200 mg, the 
usual prescribed dose for an analgesic effect, and the 
pharmacodynamic effects were compared based on time–
COX inhibition relationships.  
 
 
Methods 
Study population and design: This clinical trial was a 
randomized, single-dose, open-label, tow-treatment study 
performed on 12 healthy medical student volunteers (age 19–
20 years). Participants were listed according to the following 
condition: weight >50 kg, body mass index of 18.5–27 
kg/m
2
, Absence of clinically considerable medical history, 
physical examination detection, 12-lead electrocardiogram 
readership, or clinical laboratory-testing consequences, 
containing serum chemistry, hematology, urinalysis, and 
infected serology. The contexts and purpose were entirely 
demonstrated, and written informed consent was obtained. 
This study was approved by the Institutional Review Board 
(IRB) and Medical Ethics Committee of Babol University of 
Medical Sciences, which was carried out according to the 
Proclamation of Helsinki Good Clinical Practice. 
Chemicals and standards: All chemicals and solvents were 
of analytical grade which was purchased from Merck, 
Germany and the high-performance liquid chromatography 
(HPLC) grade solvents that were purchased from Dae-Jung, 
Korea. Ibuprofen (batch number 450025) was a gift from the 
Caspian Tamin Pharmaceutical Company (Iran). 
Preparation of chitosan-alginate as a base bead:  Sodium 
alginate and calcium chloride solutions were prepared to be 
dissolved in distilled water. The pH of the sodium alginate 
solution was adjusted at 5.1 using 0.1 N hydrochloric acid. 
Chitosan was dissolved in 1% acetic acid solution, and the 
pH was modified at 5.4 using 0.1 N NaOH. Two milliliters 
of calcium chloride solution (3.35 mg/ml) was added gently 
to 10 ml aqueous sodium alginate solution (3.0 mg/ml) and 
stirred for 30 min, and then 4 ml chitosan solution (3.0 
mg/ml) was added to the final calcium alginate gel and 
stirred for an additional 1 hour (16, 17).  
Preparation of ibuprofen loaded chitosan-alginate beads: 
A volume of 300 µl ibuprofen solution (1.105 mg/ml of an 
equal proportion of ethanol and water mixture), was 
incorporated into the calcium chloride solution. The 
remaining process was performed similarly to the preparation of 
chitosan-alginate beads without ibuprofen (figure 1).  
 
 
 
 
 
 
Figure 1. Microscopic image of A) ibuprofen loaded 
beads, B) beads without ibuprofen and C) ibuprofen powder 
 
HPLC system and operating conditions: High 
performance liquid chromatography (HPLC, Knauer, 
Germany) equipped with the fluorescent detector (Shimadzu, 
Japan) was used to measure the concentration of ibuprofen in 
serum samples. The working conditions were as follows:  the 
excitation and emission wavelengths were 224 and 290 nm, 
respectively. The column was C18 (Eurospher), and the 
mobile phase was a mixture of acetonitrile and water in a 
ratio of 40/60 acetonitrile and aqueous phosphoric acid 0.2 
(v/v %). The temperature was 25 °C, and the flow rate of the 
mobile phase was 1 ml/min.  Ezchrome software was used to 
extract area and height of the peaks. The slope, intercept, R
2 
coefficient and the coefficient variation (CV) were calculated 
for this analysis (18). 
Disintegration testing in phosphate buffers: For 
recognizing the buffer molarities corresponding to 
physiological bicarbonate buffers, disintegration test was 
used as a rapid screening test. The test was carried out using 
a hotplate stirrer and HPLC, for doing this experiment, first, 
10 cc of the buffer solution with PH 7.4 was transferred to an 
erlenmeyer 50 cc, and then 0.1 g of synthetic ibuprofen was 
added to the buffer. 100 μl of the supernatant solution was 
taken, and 20 μl of it was injected into the chromatography. 
This experiment was repeated in 0.5, 1, 2, 4 and 8-hour time 
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and then, the experiment was carried out in a buffer with PH 
2 that was similar to the gastric acidic environment. Then, in 
0.5, 1, 2, 4 and 8 hours, the ibuprofen diffusion rate was 
measured by chromatography, and the results of the 
chromatographic analysis were calculated.                                                                                      
Pharmacokinetic and pharmacodynamics assessment: 
For the pharmacokinetic evaluation the blood samples were 
obtained before dosing (0 hours) and 0.5 ,1, 1,2 ,4 ,8 ,12, and 
16 hours after administration of the drug in each term. At 
these, 6 mL of blood was extracted. The blood was poured 
into a sodium heparin tube and centrifuged at 3,000 rpm at 
4°C for 10 minutes to evaluate pharmacokinetics. To analyze 
separated plasma samples, they were frozen and stored at -
70°C. Using high-performance liquid chromatography, 
pharmacokinetic samples were analyzed. Plasma 
concentrations of ibuprofen were measured by a sensitive, 
specific and validated HPLC method using fluorescent 
detector. After thawing, each sample solution was prepared 
in acetonitrile and aqueous phosphoric acid 0.2 (v/v %).  The 
organic layer decanted and evaporated under the nitrogen 
stream at 40
o
C. The dried extract was then reconstituted with 
0.5 ml of acetonitrile and aqueous phosphoric acid 0.2 (v/v 
%) 60:40 (v/v) mixture. 
Pharmacokinetic and pharmacodynamic analysis: Using 
the noncompartmental analysis of WinNonlin® 6.4 
pharmacokinetic parameters for ibuprofen were calculated 
(Certara, Princeton, NJ, USA). The plasma concentration–
time profiles were used to obtain maximum observed plasma 
concentration (Cmax) and the time to the maximum 
concentration was observed in plasma (Tmax). After the 
administration of the drug, the area under the plasma 
concentration–time curve was estimated by the linear-up and 
log-down trapezoidal method. The slope of the terminal log-
linear phase was the elimination rate constant (λz), and by ln 
(2)/λz the terminal elimination half-life (t½) was calculated 
(19).   
Mechanism of the enteric-coated time-release capsule: 
Capsule is composed of three layers, a drug containing core 
capsule (rapid release function), the press coated polymer 
layer (Chitosan-Alginate beads layer, time release function) 
and an enteric coating layer (acid resistance function). The 
enteric coating layer does not release the drug in the stomach 
due to the acid resistance of the outer enteric coating layer. 
The enteric coating layer rapidly dissolves after gastric 
emptying and the intestinal fluid begins to slowly erode the 
press coated polymer layer. Rapid drug release occurs when 
the erosion front reaches the core polymer layer since the 
erosion process takes a long time as there is no drug release 
period (lag phase) after gastric emptying. The period of drug 
release period is controlled either by the weight or 
composition of the polymer layer (figure 2). 
 
 
 
 
 
 
 
 
 
Figure 2. Design of enteric-coated timed-release Capsule 
 
Statistical Analysis: This analysis was performed using 
SPSS software Version 16. Statistical analyses were 
performed using one-way ANOVA followed by post-hoc 
Tukey test. To compare the geometric mean ratios of AUC0–
t and Cmax pharmacokinetic values with the 90% confidence 
intervals (CIs), analysis of variance was performed using a 
mixed-effect model. The level of significance P<0.05 was 
considered statistically significant. 
 
 
Results  
In vitro study: In vitro studies showed that ibuprofen is not 
released from the alginate microbeads when incubated in 
HCl (pH=2). However, when the beads were transferred to 
phosphate-buffered saline (PBS) at a pH of 7.4, all of the 
ibuprofen is released within 7h in a 1 active form (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cumulative percent of in vitro release of 
ibuprofen (SYN) from the microbeads and commercial 
ibuprofen at 37ºC in PBS, pH 7.4 and ibuprofen in HCl, pH 2.0 
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Pharmacokinetics: Pharmacokinetic indexes (Tmax, Cmax, 
and AUC0–t) are demonstrated in table 1 and figure1. The 
median Tmax of ibuprofen, ibuprofen arginine and 
solubilized ibuprofen capsule were 1.25, 0.42 and 0.5 hours, 
respectively. Ibuprofen has a significant difference with 
ibuprofen arginine and solubilized ibuprofen capsule 
(P<0.001). After the oral intake of 200 mg of ibuprofen, the 
Cmax was lower in ibuprofen and the AUC0–t was equivalent 
when evaluating the systemic exposures of ibuprofen and 
solubilized ibuprofen capsule compared to ibuprofen 
arginine. Also, the t½ and apparent clearance in the 
elimination process was not significantly different among the 
three groups (P=0.813 and P=0.906, respectively).  
The enteric-coated ibuprofen product tends to 
disintegrate longer than the ibuprofen tablet. Comparison of 
ibuprofen concentration shows a statistical difference 
between the two groups (table 1). Besides, a higher 
concentration was observed in the group receiving enteric-
coated ibuprofen taking 4h after dosing. Ibuprofen 
concentration in serum increased rapidly to the maximum 
level after 1 hour in the group receiving regular tablet form 
and increased enteric-coated after 4 hours. The maximum 
and minimum concentrations of ibuprofen at 1 hour were 
11.7 and 0.01 µg/ml for ibuprofen tablet and 10.32 and 0.82 
µg/ml for enteric-coated form, respectively (table 1).  
 
Table 1. Pharmacokinetic parameters of ibuprofen after 
single oral administration of ibuprofen tablet (200 mg) 
and (ibuprofen rnteric-coated capsule (200 mg) in 
healthy volunteers 
Parameter  Ibuprofen
tablet 
 coated-entric Ibuprofen
capsule 
T max (hours) 1 4 
Cmax (µg/ml) 11.71 10.32 
AUC0–t  (mg⋅h/l) 61.51 82.62* 
Cmax: maximum concentration;         Tmax: time to Cmax;          
AUC: area under the blood level curve          * Significant 
differences at p ≤ 0.05 between two groups 
 
The standard curve: To determine the concentration of the 
serum samples, the standard curve was plotted with a minimum 
of 4 concentrations of ibuprofen in the standard solution 
(figures 4, 5). Standard curves of ibuprofen at 10, 20, 40 and 
80 µg/mL were prepared. R
2
 (linearity) parameter is also 
depicted in the chart. The coefficient of variation (CV) was 
obtained based on the area under the curve, which was 4.75%. 
Safety and tolerability: There were no adverse events 
relevant to drugs of our research. There was no report about 
clinically significant physical checkup findings, vital signs, 
laboratory abnormalities and electrocardiogram results. None 
of these adverse events were discontinued in our research. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Linearity plot for ibuprofen standards at 10, 20, 
40 and 80 µg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The sample HPLC peaks of ibuprofen (RT: 5.4 
min). A) Standard ibuprofen (10µg/ml); B) standard 
ibuprofen (20µg/ml); C) serum sample after 1h ibuprofen 
received 
 
 
Discussion 
The NSAIDs’ GI (gastro-intestinal) side effects have 
been widely reported, especially in patients with painful 
chronic diseases (20). To avoid the GI side effects, enteric-
coated forms have been suggested (16). The results of this 
study have shown that the designed enteric-coated dosage 
form of ibuprofen can deliver ibuprofen in the gut in a 
controlled manner. However, benefitting from such a biogel-
based delivery system requires more detailed studies, mostly 
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focused on the gut tissue absorption mechanism. Enteric-
coated drugs remain unaffected by the acidic medium of the 
stomach and deliver their active material to the alkaline 
setting of the gut. Additionally, enteric-coatings are used in 
many other cases, including in drugs that are sensitive to the 
gastric acid, e.g. pantoprazole, or in cases where the drug is 
required to affect the gut tissue directly, such as sulfasalazine 
(21).  
 To escape gastric degradation, this kind of dosage forms 
should not be crushed, chewed, or split in half when 
administered. It is also recommended to receive the dosage 
forms on an empty stomach, otherwise there is a possibility 
of the mentioned enteric-coated drugs to disintegrate in the 
medium. The oral bioavailability of a drug depends on the 
target of delivery, the pathway of drug absorption, the 
physiological conditions, and the physicochemical properties 
of the compounds.   
Ibuprofen, as a weak acid (pKa= 4.4), is able to dissolve 
in acidic pH media. This property could have the key effect 
on plasma drug concentration. To enhance water solubility, 
manufacturing salt forms of the acidic drugs have been 
suggested as a practical method, one that does not affect the 
drug bioavailability (22). 
It has been previously reported that the more soluble 
form of ibuprofen shows a higher rate of absorption (lower 
Tmax  and higher Cmax) compared to the regular drug form 
(15, 23).  
Additionally, based on a clinical trial after oral 
administration of single dose (200 mg) of two formulations 
of ibuprofen, the Cmax of arginine ibuprofen was shown to be 
equal to regular ibuprofen, while the average Tmax for 
ibuprofen was significantly delayed compared to the other 
dosage form. As a result, formulating more soluble drug 
forms leads to a higher rate of absorption, followed by a 
larger Cmax and smaller Tmax which happens while preserving 
the other pharmacokinetic processes. In general, if the goal is 
to manage severe pains more rapidly and efficiently, 
formulations with a faster rate of absorption are suggested, 
where decreasing the drug concentration or delaying drug 
delivery might fail the treatment process. On the contrary, 
the use of such rapidly-absorbable formulations in patients 
with GI problems will exacerbate the pain and fail the 
treatment.  
To avoid GI damages in NSAID’s administration, in this 
study we managed to design a method for making enteric-
coated ibuprofen. The serum samples were analyzed using 
the method of HPLC, each individual having received 200 
mg of the prepared ibuprofen (and in a parallel study, the 
more soluble form). It was observed that the Tmax of the 
prepared drug is 4 hours after drug administration, which is 
delayed 2 hours compared with the soluble ibuprofen. 
Additionally, the AUC of the enteric-coated was reported 
(figure 6) to be higher than that of the soluble ibuprofen.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6. Mean and standard deviation of plasma 
concentration–time profiles of ibuprofen in all healthy 
subjects after a single 200 mg oral dose 
 
In conclusion, the obtained results from both in vivo and in 
vitro trials show that our formulation of the enteric coated 
ibuprofen can bypass the acidic environment of the stomach 
as well as delivering in the small intestine. Such 
administration of ibuprofen seems to be more useful for 
patients with gastrointestinal diseases. Additionally, in the 
mentioned property, this formulation can maintain an 
adequate level of drug concentration in the blood serum at 
least 4 hours after administration, which makes it a more 
effective painkiller through larger time intervals. 
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